The CA 125 radioimmunoassay has been increasingly used to monitor the course of
patients with ovarian epithelial carcinomas. The purpose of this report is to describe our …

In a prospective study, the serum levels of CA 125 were estimated at regular intervals in 139
patients with ovarian carcinoma. Seventy-two of 78 patients with a second-look laparotomy …

Thirty-one patients with ovarian cancer were monitored with the CA 125 antigenic
determinant in the interval between cytoreductive surgery and the completion of sub …

Serum CA 125 levels were evaluated in 227 patients with ovarian cancer. CA 125 levels
were elevated in 86% of the patients. All histologic types, including mucinous tumors, were …

Serum CA 125 levels and surgical findings were prospectively compared in 96 secondary
laparotomies performed on patients with epithelial ovarian cancer. All patients had …

CA 125, which is an antigenic determinant expressed by many epithelial ovarian cancers, is
measured in serum using a solid phase immunoradiometric assay. Sera from 55 patients …

Serum CA 125 levels were obtained from 55 women with epithelial ovarian cancer before a
second-look surgical procedure and serially thereafter. All patients were clinically and …

The prognostic significance of serum CA 125 level measured in the week before second-
look operation was evaluated in 208 patients with invasive epithelial ovarian cancer. Serum …

Second-look laparotomy is performed to evaluate response to chemotherapy and to
determine the need for additional treatment. The relationship between absolute levels of …

The monoclonal antibody-based serum assay for CA 125 is a reliable indicator of tumor
status in patients with ovarian cancer. This noninvasive technique also permits …